Immune checkpoint blockade with monoclonal antibodies (mAbs) to programmed cell death receptor-1 (PD-1) (nivolumab and pembrolizumab) and PD-1 ligand-1 (PD-L1) (atezolizumab, avelumab, and durvalumab) alone or in combination with chemotherapy, radiotherapy, or bevacizumab is an expanding treatment strategy for metastatic non-small-cell lung cancer (mNSCLC), malignant melanoma, head and neck cancer, kidney and urological cancer, and other common malignancies. The gene discussed is CD274; the disease is melanoma.